<bill session="114" type="h" number="6348" updated="2023-01-11T13:34:03Z">
  <state datetime="2016-11-17">REFERRED</state>
  <status>
    <introduced datetime="2016-11-17"/>
  </status>
  <introduced datetime="2016-11-17"/>
  <titles>
    <title type="display">To extend for two years the program for priority review to encourage treatments for rare pediatric diseases.</title>
    <title type="official" as="introduced">To extend for two years the program for priority review to encourage treatments for rare pediatric diseases.</title>
  </titles>
  <sponsor bioguide_id="G000556"/>
  <cosponsors/>
  <actions>
    <action datetime="2016-11-17">
      <text>Introduced in House</text>
    </action>
    <action datetime="2016-11-17" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="114" type="h" number="6347" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2016-12-06T16:13:59Z" status="Introduced in House">This bill amends the Federal Food, Drug, and Cosmetic Act to extend through 2018 the priority review voucher program for treatments for rare pediatric diseases. (A priority review voucher is a transferable voucher that entitles the holder to have a new drug or biological product application acted upon by the Food and Drug Administration within six months.)</summary>
</bill>
